Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19547056 | 0.83 | HRH4 (0.55) | ALDH1A1HRH4KDM4EGAAMEN1 | |
| SCHEMBL29886325 | 0.81 | ALDH1A3 (0.49) | MAPTSMN1; SMN2ALDH1A1HRH4TRIM24 | |
| SCHEMBL786129 | 0.81 | ALDH1A3 (0.49) | MAPTSMN1; SMN2ALDH1A1HRH4TRIM24 | |
| SCHEMBL1715756 | 0.80 | PIK3CA (0.57) | SMN1; SMN2HTTALDH1A1KDM4E | |
| SCHEMBL14232379 | 0.80 | HRH4 (0.50) | MAPTSMN1; SMN2ALDH1A1HRH4TRIM24 | |
| SCHEMBL23048714 | 0.79 | HRH3 (0.41) | MAPTSMN1; SMN2ALDH1A1HRH4KDM4E | |
| SCHEMBL23048648 | 0.79 | HRH3 (0.45) | MAPTALDH1A1HRH4KDM4E | |
| SCHEMBL1914800 | 0.77 | PIM1 (0.58) | MAPTSMN1; SMN2GAARAB9AMEN1 | |
| SCHEMBL1914804 | 0.77 | PIM1 (0.58) | MAPTSMN1; SMN2GAARAB9AMEN1 | |
| SCHEMBL1914806 | 0.77 | PIM1 (0.58) | MAPTSMN1; SMN2GAARAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9157077-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-9157077-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-9157077-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2516425-B1 | AMINOPYRIMIDINE KINASE INHIBITORS | JASCO PHARMACEUTICALS LLC (US) | 2015-09-02 | — | — | EP | disclosed |
| EP-2516425-B1 | AMINOPYRIMIDINE KINASE INHIBITORS | JASCO PHARMACEUTICALS LLC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-20140080799-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080799-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080799-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2014-03-20 | — | — | US | disclosed |
| US-8563539-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563539-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563539-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2013-10-22 | — | — | US | disclosed |
| EP-2516425-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals LLC (US) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011079274-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals, LLC (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079274-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals, LLC (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152235-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152235-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152235-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080799-A1 | Aminopyrimidine Kinase Inhibitors | PIM1, PIM2, PIM3 | MAPT 1448/4885SMN1; SMN2 3555/4885HTT 4057/4885 |
| US-20110152235-A1 | Aminopyrimidine Kinase Inhibitors | PIM1, PIM2, PIM3 | MAPT 1427/4885SMN1; SMN2 3598/4885HTT 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.